Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

21. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. (Abstract)

Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Intradialytic hypotension (IDH) is a common complication of haemodialysis (HD), and a risk factor of cardiovascular morbidity and death. Several clinical studies suggested that reduction of dialysate temperature, such as fixed reduction of dialysate temperature or isothermal dialysate using a biofeedback system, might improve the IDH rate.This review aimed to evaluate (...) the benefits and harms of dialysate temperature reduction for IDH among patients with chronic kidney disease requiring HD, compared with standard dialysate temperature.We searched Cochrane Kidney and Transplant's Specialised Register up to 14 May 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search

2019 Cochrane

22. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. (Abstract)

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bone demineralisation and is associated with adverse kidney outcomes and mortality. Veverimer, a non-absorbed, counterion-free, polymeric drug candidate selectively binds and removes hydrochloric acid from the gastrointestinal (...) lumen.We did a multicentre, randomised, blinded, placebo-controlled, 40-week extension of a 12-week parent study at 29 sites (hospitals and specialty clinics) in seven countries (Bulgaria, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA). Eligible patients were those with chronic kidney disease (estimated glomerular filtration rate 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate 12-20 mmol/L), who had completed the 12-week parent study, for which they were randomly assigned

2019 Lancet Controlled trial quality: predicted high

23. Use of Peripherally Inserted Central Catheters in Patients With Advanced Chronic Kidney Disease: A Prospective Cohort Study. (Abstract)

Use of Peripherally Inserted Central Catheters in Patients With Advanced Chronic Kidney Disease: A Prospective Cohort Study. Existing guidelines, including Choosing Wisely recommendations, endorse avoiding placement of peripherally inserted central catheters (PICCs) in patients with chronic kidney disease (CKD).To describe the frequency of and characteristics associated with PICC use in hospitalized patients with stage 3b or greater CKD (glomerular filtration rate [GFR] <45 mL/min/1.73 m2

2019 Annals of Internal Medicine

24. Growth Monitoring for Children with Chronic Kidney Disease

Growth Monitoring for Children with Chronic Kidney Disease S Trace, E Cameron, C Inward, CP Burren, Feb 2019 Review date Feb 2022 Page 1 of 5 Bristol Royal Hospital for Children Growth Monitoring Guideline for Children with CKD Contents Page 1-2 Scope, Background, Rationale and Evidence base for guideline Page 2 Definition of Stages of Chronic Kidney Disease (CKD) Page 3 Notes on Growth Monitoring and Referral Page 4 Growth Monitoring Timetable Page 5 References The guideline scope extends (...) and reviews. Multiple measures are necessary 8,9 to give a broad and reliable picture of Clinical Guideline MONITORING GROWTH IN CHILDREN WITH CHRONIC KIDNEY DISEASE S Trace, E Cameron, C Inward, CP Burren, Feb 2019 Review date Feb 2022 Page 2 of 5 Bristol Royal Hospital for Children Growth Monitoring Guideline for Children with CKD growth and nutrition, and the frequency of measurement will depend on the child’s age and stage of CKD (see page2). Children displaying growth delay or unstable medical

2019 British Society for Paediatric Endocrinology and Diabetes

25. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis (Abstract)

Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis Data regarding the efficacy and safety of warfarin and non-vitamin K antagonist oral anticoagulant (NOAC) among patients with chronic kidney disease (CKD) remain scarce.Systematic review and meta-analysis of studies involving patients with CKD treated with oral anticoagulants were conducted to evaluate the following outcomes: ischemic stroke, intracerebral hemorrhage (ICH), combined ischemic

2019 EvidenceUpdates

26. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac Full Text available with Trip Pro

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the sodium-glucose co (...) groups. There were no new drug-related safety signals.Dapagliflozin with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentially attractive option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.AstraZeneca.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 EvidenceUpdates

27. Undernutrition in Chronic Kidney Disease

Undernutrition in Chronic Kidney Disease Clinical Practice Guideline Undernutrition in Chronic Kidney Disease Authors: Dr Mark Wright Consultant Nephrologist, St J am es ’s University Hospital, Leeds Mrs Elizabeth Southcott Senior Specialist Renal Dietitian, St J a m es’s University Hospital, Leeds Dr Helen MacLaughlin, Consultant Dietitian, Kings College Hospital Mr Stuart Wineberg Patient Representative Final Version: June 2019 Review Date: June 2024 2 Endorsements The National Institute (...) with extensive atherosclerotic disease in a particularly toxic combination that is associated with increased mortality risk 3 . The International Society of Renal Nutrition and Metabolism (ISRNM), recommend the term protein energy wasting (PEW) to describe the undernutrition that is prevalent in renal failure populations 4 , though more than one underlying cause may present in any individual. Protein energy wasting is described in 20-40% of patients with stage 4-5 chronic kidney disease (CKD) 3

2019 Renal Association

28. Interventions for improving sleep quality in people with chronic kidney disease. (Abstract)

Interventions for improving sleep quality in people with chronic kidney disease. Sleep disorders are commonly experienced by people with chronic kidney disease (CKD). Several approaches for improving sleep quality are used in clinical practice including relaxation techniques, exercise, acupressure, and medication.To assess the effectiveness and associated adverse events of interventions designed to improve sleep quality among adults and children with CKD including people with end-stage kidney (...) disease (ESKD) treated with dialysis or kidney transplantation.We searched the Cochrane Kidney and Transplant Register of Studies up to 8 October 2018 with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) or quasi-randomised RCTs

2019 Cochrane

29. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. Full Text available with Trip Pro

Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. To investigate the relation between preterm birth (gestational age <37 weeks) and risk of CKD from childhood into mid-adulthood.National cohort study.Sweden.4 186 615 singleton live births in Sweden during 1973-2014.Gestational age at birth, identified from nationwide birth records in the Swedish birth registry.CKD, identified from nationwide inpatient and outpatient diagnoses through 2015

2019 BMJ

30. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. (Abstract)

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.We did this double-blind, randomised, placebo-controlled trial (...) % with no substantial fluid retention during the enrichment period (responders) were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days) or end-stage kidney disease (eGFR <15 mL/min per 1·73 m2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney

2019 Lancet Controlled trial quality: predicted high

31. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. (Abstract)

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Patients with advanced chronic kidney disease lose the capacity to fully excrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease progression and causes muscle catabolism and bone resorption. Veverimer, a non-absorbed, counterion-free, polymeric drug, selectively binds and removes (...) participants were patients aged 18-85 years with non-dialysis-dependent chronic kidney disease (estimated glomerular filtration rate of 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate concentration of 12-20 mmol/L). Patients were randomly assigned (4:3) to veverimer 6 g/day or placebo for 12 weeks while they consumed their typical diet. Both drugs were taken as oral suspensions in water with lunch. Randomisation was done by study site personnel with a computer-generated randomisation

2019 Lancet Controlled trial quality: predicted high

32. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis Full Text available with Trip Pro

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycaemic efficacy is dependent on kidney function. We performed a systematic review and meta-analysis to assess the efficacy and safety

2019 EvidenceUpdates

33. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. (Abstract)

Parenteral versus oral iron therapy for adults and children with chronic kidney disease. The anaemia seen in chronic kidney disease (CKD) may be exacerbated by iron deficiency. Iron can be provided through different routes, with advantages and drawbacks of each route. It remains unclear whether the potential harms and additional costs of intravenous (IV) compared with oral iron are justified. This is an update of a review first published in 2012.To determine the benefits and harms of IV iron (...) supplementation compared with oral iron for anaemia in adults and children with CKD, including participants on dialysis, with kidney transplants and CKD not requiring dialysis.We searched the Cochrane Kidney and Transplant Register of Studies up to 7 December 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register

2019 Cochrane

34. Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension

Albumin:creatinine ratio testing in the assessment and/or identification of proteinuria in people with chronic kidney disease or primary hypertension Page 1 of 6 TER005 December 2018 Topic Exploration Report Topic explorations are designed to provide a high-level briefing on new topics submitted for consideration by Health Technology Wales. The main objectives of this report are to: 1. Inform discussions on new topics received by HTW. 2. Determine the quantity and type of evidence available (...) on a topic. 3. Assess the topic against HTW selection criteria. Topic: Albumin:creatinine ratio (ACR) ) testing compared to protein:creatinine ratio (PCR) testing for the detection of proteinuria in patients with hypertension and/or chronic kidney disease Topic exploration report number TER005 Referrer: Dr Soha Zouwail, Consultant Chemical Pathologist, Cardiff and Vale University Health Board Topic exploration undertaken by: Health Technology Wales Aim of Search Health Technology Wales researchers

2019 Health Technology Wales

35. Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease

Patiromer (Veltassa) - for the treatment of hyperkalemia in adults with chronic kidney disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs

2019 Health Canada - Drug and Health Product Register

36. New generation anticoagulants may be safer than warfarin for people with chronic kidney disease

New generation anticoagulants may be safer than warfarin for people with chronic kidney disease New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Discover Portal Discover Portal New generation anticoagulants may be safer than warfarin for people with chronic kidney disease Published on 26 April 2016 doi: Newer generation anticoagulants appear to reduce the risk of bleeding compared with older anticoagulants like warfarin, when used to prevent clots (...) in people who also have mild to moderate chronic kidney disease. This group of drugs, called direct oral anticoagulants, have been well researched in healthy people with atrial fibrillation or at risk of thromboembolism but this was the first review to look at their safety, in terms of bleeding and risk of bleeding within the brain, in people with kidney disease. As a group, these newer drugs appear safer than older anticoagulants such as warfarin. Evidence from the trials comparing individual new

2019 NIHR Dissemination Centre

37. Gout medication may slow progression of chronic kidney disease

Gout medication may slow progression of chronic kidney disease Gout medication may slow progression of chronic kidney disease Discover Portal Discover Portal Gout medication may slow progression of chronic kidney disease Published on 20 February 2018 doi: In people with existing kidney disease, one in four will have worse disease within six to 12 months. Uric acid-lowering drugs such as allopurinol halve the risk of disease progression over this period. They also reduce heart attack or stroke (...) by 60%. Uric acid, the cause of gout, is produced when proteins are broken down by the body. It is excreted by the kidneys and often builds up in people with chronic kidney disease. It is not certain whether increased uric acid causes progression of kidney disease or is simply a marker of its severity. This review included 16 small trials of 1,211 people with moderate chronic kidney disease from a variety of causes which were allocated to take a uric acid lowering medication or usual care. Although

2019 NIHR Dissemination Centre

38. Uncertainty persists over choice of phosphate binders for chronic kidney disease

Uncertainty persists over choice of phosphate binders for chronic kidney disease Uncertainty persists over choice of phosphate binders for chronic kidney disease Discover Portal Discover Portal Uncertainty persists over choice of phosphate binders for chronic kidney disease Published on 30 August 2016 doi: NICE recommend calcium-based phosphate binding medicines for people with chronic kidney disease, however, new research suggests non-calcium based alternatives might lead to a lower risk (...) of death. The review is best viewed alongside other reviews which look at different aspects of chronic kidney disease. The totality of research and cost effectiveness will need to be considered if practice recommendations are to change. In this review, calcium-based phosphate binders were associated with increased risk of death compared with non-calcium alternatives, but there was no difference in the risk of cardiovascular death or hospitalisation. Effects of these agents on mortality need

2019 NIHR Dissemination Centre

39. Prevalence of depression and associated factors among patients with chronic kidney disease in east Africa: a systematic review and meta-analysis

Prevalence of depression and associated factors among patients with chronic kidney disease in east Africa: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) ); sex (stratified per sex); duration of index ischemia (linear); stem cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models

2019 PROSPERO

40. Prevalence of chronic kidney diseases in patients with diabetes mellitus in the middle east: a systematic review

Prevalence of chronic kidney diseases in patients with diabetes mellitus in the middle east: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO